{"favorite_id": 4053, "calc_type": "", "dosing": false, "full_title_en": "Mantle Cell Lymphoma International Prognostic Index (MIPI)", "short_title_en": "MIPI", "medium_description_en": "Predicts survival in patients with mantle cell lymphoma.", "short_description_en": "Mantle cell lymphoma survival.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Hematologic Malignancy", "Leukemia/Lymphoma"], "specialty_en": ["Hematology and Oncology"], "chief_complaint_en": ["Abdominal Pain", "Fatigue", "Fever", "Lymphadenopathy", "Vomiting"], "system_en": ["Hematologic", "Oncologic"], "search_abbreviation_en": ["MCL", "mantle cell lymphoma", "lymphoma", "mantle cell lymphoma international prognostic index", "international prognostic index", "MIPI", "IPI", "mantel cell"], "slug": "mantle-cell-lymphoma-international-prognostic-index-mipi", "seo": {"meta_description_en": "MIPI for mantle cell lymphoma stratifies patients with MCL into three risk categories. ", "keywords_en": "Prognostic index, mantle cell lymphoma, MCL, MCL international prognostic index, MIPI, FLIPI, IPI, lymphoma, non-Hodgkin lymphoma, malignant lymphoma, revised European-American Lymphoma classification, REAL, hematology, oncology, advanced stage MCL, chemotherapy, CHOP, R-CHOP,  MCP"}, "content": {"how_to_use": {"use_case_en": "<p>Use in patients presenting with advanced stage mantle cell lymphoma, to help prognosticate and potentially determine therapy. </p>", "pearls_pitfalls_en": "<ul> <li>While most patients with advanced mantle cell lymphoma need to be treated soon after diagnosis, there is growing recognition of a small percentage of very low risk patients who may not need treatment for a much longer period. </li> <li>If Ki-67 is available, it can be added to calculate the MIPIb or \u201cbiologic\" score. </li> </ul>", "why_use_en": "<p>The MIPI is more specific to mantle cell lymphoma than the <calculator id=\"3936\">International Prognostic Index (IPI)</calculator>.</p>"}, "next_steps": {"advice_en": "<ul> <li>The MIPI categorizes patients into 3 risk groups: low, intermediate, or high.</li> <li> Low-risk patients may be considered for close observation if there are no other indications for treatment.</li> <li>However, both intermediate and high risk patients are treated with immunochemotherapy either alone or followed by autologous stem cell transplantation depending on many other patient factors such as age, comorbidities, side effect profiles, and patient preferences.</li> </ul>", "management_en": "<p>There is diversity in clinical practice for the treatment of mantle cell lymphoma, with very few head-to-head studies of the various approaches. While we know a small number of patients with low-burden, low-risk disease may have an indolent course, it is difficult to identify those patients at diagnosis. Most patients will need treatment at diagnosis even though current treatment paradigms are not considered curative. The standard treatments are induction chemoimmunotherapy followed by autologous stem cell transplantation with or without maintenance. </p>", "critical_actions_en": ""}, "about": {"formula_en": "<p>MIPI = ( 0.03535 \u00d7 age ) + 0.6978 (if ECOG &gt;1) + [ 1.367 \u00d7 log10 ( LDH / <abbr title=\"Upper limit of normal\">ULN</abbr> ) + 0.9393 \u00d7 log10 ( WBC ) ]</p> <p><strong>If Ki-67 is available:</strong><br>MIPIb = ( 0.03535 \u00d7 age ) + 0.6978 (if ECOG &gt;1) + [ 1.367 \u00d7 log10 ( LDH / ULN ) + 0.9393 \u00d7 log10 ( WBC ) ] + ( 0.02142 x Ki-67 )</p>", "more_info_en": "<p>Interpretation:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>MIPI</strong></p>\n</td>\n<td>\n<p><strong>Risk</strong></p>\n</td>\n<td>\n<p><strong>Median overall survival</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&lt;5.7</p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>Not reached (5 year survival 60%)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5.7 to &lt;6.2</p>\n</td>\n<td>\n<p>Intermediate</p>\n</td>\n<td>\n<p>51 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&ge;6.2</p>\n</td>\n<td>\n<p>High</p>\n</td>\n<td>\n<p>29 months</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>MIPIb</strong></p>\n</td>\n<td>\n<p><strong>Risk</strong></p>\n</td>\n<td>\n<p><strong>Median overall survival</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&lt;5.7</p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>Not reached</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5.7 to &lt;6.5</p>\n</td>\n<td>\n<p>Intermediate</p>\n</td>\n<td>\n<p>58 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&ge;6.5</p>\n</td>\n<td>\n<p>High</p>\n</td>\n<td>\n<p>37 months</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>From <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17962512\">Hoster 2008</a>.</p>", "evidence_based_medicine_en": "<p>The MIPI was described in <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17962512\" target=\"_blank\">2008</a> using data on 455 patients from 3 clinical trials ranging from 1996-2004. A Cox regression analysis was used to backwards calculate the variables included in the MIPI, and validation was performed on the same training set by bootstrap method of validation.</p> <p>It was later independently validated in <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24687837\" target=\"_blank\">2014</a> using data on 958 patients from 2 separate clinical trials from 2004-2010. This study confirmed the prognostic value of the 3 groups but with different estimated 5-year survival rates, likely reflecting the differences in the patient population and treatment. As such, the score needs to be interpreted with these factors in mind when applied to the individual patient.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/17962512 ", "text": "Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/26926679 ", "text": "Hoster E, Rosenwald A, Berger F, et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34(12):1386-94."}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436357/", "text": "Lim SY, Horsman JM, Hancock BW. The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?. Oncol Lett. 2010;1(1):187-188."}], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/24687837", "text": "Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32(13):1338-46."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/20032504", "text": "Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530-3."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Justin Taylor, MD, is an assistant professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He is board certified in internal medicine and medical oncology. He completed his internship and residency at Brigham and Women\u2019s Hospital in Boston. His clinical and research focuses are on the basic biology and translational significance of somatic genetic mutations in hematologic malignancies.</p>", "firstName": "Justin", "img": "https://cdn-web-img.mdcalc.com/people/justin-taylor.jpg", "lastName": "Taylor", "name": "Justin Taylor, MD", "target": "justin-taylor", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Eva Hoster", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Eva Hoster, PhD, is a professor of clinical epidemiology and medical biometry at Ludwig Maximilian University in Munich, Germany. She also serves as a researcher at the Institute for Medical Information Processing, Biometrics, and Epidemiology. Dr. Hoster\u2019s primary research interests involve biometric consultation and supervision of medical, doctoral, and clinical research studies and projects.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-eva-hoster.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Hoster+E%5Bau%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"label_en": "Age", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "age", "unit": "age", "type": "textbox", "unit_info": {"name": "Age", "conversion": 1, "error_min": 0.001, "error_max": 120, "warn_min": 0.1, "warn_max": 100, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "years", "units_us": "years"}}, {"type": "toggle", "label_en": "<calculator id='3170'>ECOG</calculator>", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "0-1", "value": 0}, {"label": "2-4", "value": 1}], "name": "ecog"}, {"label_en": "Serum LDH", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "ldh", "unit": "ldh", "type": "textbox", "unit_info": {"name": "Serum LDH", "conversion": 1, "error_min": 0, "error_max": 5000, "warn_min": 60, "warn_max": 160, "normal_max_si": 160, "normal_min_si": 60, "normal_min_us": 60, "units_si": "U/L", "units_us": "U/L", "normal_max_us": 160}}, {"label_en": "Upper limit of normal for serum LDH", "conditionality": "", "default": 160, "tips_en": "According to your lab's normal values", "optional": false, "name": "ulnldh", "unit": "ldh", "type": "textbox", "unit_info": {"name": "Serum LDH", "conversion": 1, "error_min": 0, "error_max": 5000, "warn_min": 60, "warn_max": 160, "normal_max_si": 160, "normal_min_si": 60, "normal_min_us": 60, "units_si": "U/L", "units_us": "U/L", "normal_max_us": 160}}, {"label_en": "WBC", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "wbc", "unit": "wbc", "type": "textbox", "unit_info": {"name": "White Blood Cell Count", "conversion": 1, "error_min": 0.0001, "error_max": 500, "warn_min": 0.1, "warn_max": 100, "normal_max_si": 10.7, "normal_min_si": 3.7, "normal_min_us": 3.7, "units_si": "\u00d7 10\u2079 cells/L", "units_us": "\u00d7 10\u00b3 cells/\u00b5L", "normal_max_us": 10.7}}, {"label_en": "Ki-67", "conditionality": "", "default": null, "tips_en": "Optional, for MIPIb", "optional": true, "name": "index", "unit": "ki67", "type": "textbox", "unit_info": {"name": "Ki-67", "conversion": 1, "error_min": 0, "error_max": 100, "warn_min": 0, "warn_max": 20, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "%", "units_us": "%", "normal_max_us": 20}}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 3936, "short_title_en": "IPI and R-IPI", "slug": "international-prognostic-index-diffuse-large-b-cell-lymphoma-ipi-r-ipi"}, {"calcId": 4054, "short_title_en": "CLL-IPI", "slug": "international-prognostic-index-chronic-lymphocytic-leukemia-cll-ipi"}, {"calcId": 2320, "short_title_en": "FLIPI for Follicular Lymphoma", "slug": "follicular-lymphoma-international-prognostic-index-flipi"}]}